GlassScriptPhysician profile
Anna L Cheek
NPI 1891313177
$540.39
in general payments reported to CMS, 2019-2025
15 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $67.74 · 2023: $53.21 · 2024: $122 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.01 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $122.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $102.47 | 2023-2025 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $61.41 | 2022-2025 | |
| Ambu INC. | $34.17 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.02 | 2025 | Ofev |
| Abiomed | $30.86 | 2024 | Impella |
| United Therapeutics Corporation | $28.94 | 2025 | |
| Harmony Biosciences LLC | $22.04 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2024 | Uptravi, Opsumit |
| Aurinia Pharma U.S., INC. | $15.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.85 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $14.31 | 2025 | Dupixent |
| Viatris Specialty LLC | $13.92 | 2025 | Yupelri |
| Verona Pharma, INC. | $13.81 | 2025 | Ohtuvayre |
| Amgen INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Cheek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.